Infliximab is an anti-tumour necrosis factor-α (Anti-TNF) antibody. It is from a group of drugs called cytokine inhibitors. Cytokines are small protein molecules, which occur in the body and are involved in inflammatory conditions.
Infliximab binds to these molecules and inhibits the inflammatory response.
Infliximab is currently used at GHNHSFT within the NICE Technology Appraisals to treat a number of inflammatory conditions. This includes Ulcerative Colitis, Crohn’s Disease, Rheumatoid Arthritis and Psoriasis.